Kansas nonprofit gains new partnership to help families battling rare diseases
WICHITA, Kan. (KSNW) – While rare diseases are scarce, collectively they are more common than people realize.
'Rare diseases infect one in 10 people,' said Blake Benton. 'That could be your neighbor, someone you go to church with, someone at the grocery store, that's fighting something that may not be apparent on the outside, but at home, it can be making a major difference and a strain in their house.'
Blake Benton saw the challenges caregivers face firsthand.
'You can be completely lost, you know, when it's your loved one. Most oftentimes, you're not coming from a medical background and so you are just learning on the fly,' he said.
Blake's older brother, Ryan Benton, had Duchenne muscular dystrophy.
'He never wanted the disease to define him,' he said.
Ryan was a musician and an advocate.
Bosom Buddies is a friend to nursing moms in Saline County
'So many times in this journey it feels like one step forward, two steps back,' said Ryan during an interview with KSN in February 2023.
Ryan and Blake started Coming Together for a Cure. The nonprofit aims to help advance stem cell therapy and be a go-to resource to help people fighting rare diseases.
'Families don't realize that these things are out there so often,' Blake, co-founder and director of strategic initiatives for CTFAC, said.
In March, the nonprofit partnered with Cariloop to give families free access to its caregiver support platform.
'They get connected to an actual person that can immediately understand their direct needs,' Blake explained. 'Then, they can guide them to the specific tools and resources that can help them through their daily life.'
The Cariloop coaches can help schedule appointments, manage documents, and offer emotional support.
'You can just focus on living your best life,' Blake said. 'By having these caregiving solutions designed in a way that really fits your specific needs. It just makes life easier for everybody.'
It relieves stress that can build under the pressure of caregiving.
'There was a brief period where I didn't feel like I was his brother first. I was his caregiver first,' Blake recalled.
Kansas couple turns passion of reptiles into rescue
Blake can attest that having help on the journey lets bonds stay tight.
'It was like we were brothers again. He was my best friend, and I didn't have to deal with just being this person he had to rely on, but I could step in when I wanted to not because I had,' he said.
Even though he's gone, Blake brings Ryan's memory with him daily as CTFAC grows.
'I think Ryan would be very proud that his legacy has lived through,' he said.
The partnership with Cariloop is the first major collaboration to expand CTFAC's Trusted Support Network.
CTFAC serves families in Kansas and all over the world. If you are interested in getting connected to resources or learning more about stem cell therapy, click here.
If you would like to nominate a nonprofit for our Here For You Spotlight, fill out our online contact form.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
SpliceBio lands $135M for a new kind of eye gene therapy
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. SpliceBio, a Spanish biotechnology company working on next-generation gene therapies, said Wednesday it raised $135 million in a Series B round to advance its lead program in Stargardt disease into further clinical testing. The startup is built around a technology that's meant to overcome a key limitation of current gene therapies. Scores of gene therapy developers use adeno-associated viruses, or AAVs, to deliver genetic cargo into the body. But because of their small size, AAVs can't carry larger corrective genes, leaving many diseases out of reach or forcing companies to come up with creative solutions. One example is in Duchenne muscular dystrophy. Because of the large size of the gene coding for the muscle-protecting protein dystrophin Duchenne patients lack, several companies, like Sarepta Therapeutics, have developed gene therapies that make a shortened form. The approach comes with drawbacks, however, as a truncated version of the protein might not work as well as the original. SpliceBio has a different workaround. The company is using two separate AAVs to send pieces of a large gene into cells. Once inside, specially engineered splicing molecules help reassemble their cargo into full-length proteins. Stargardt disease, for example, is caused by mutations to the ABCA4 gene, which is too large to stuff into an AAV. SpliceBio says its method can help the body produce a functional version of the protein that gene produces. Its lead program, SB-007, is in a Phase 1/2 trial. SpliceBio isn't the only biotech pursuing this type of approach to treat Stargardt, an inherited eye condition that causes progressive vision loss. Another European company, AAVantgarde, has a similar type of program in early-stage testing. SpliceBio's technology is based on research conducted at Princeton University, where co-founder and CEO Miquel Vila-Perelló was studying protein design and engineering. Launched in 2014 under the name ProteoDesign, the biotech is also working on additional programs in ophthalmology, neurology and other undisclosed therapeutic areas. Its Series B round was co-led by EQT Life Sciences and Sanofi Ventures, and involved seven other backers including Roche Venture Fund, New Enterprise Associates and Novartis Venture Fund. "The support from such high-quality investors underscores the strength of our programs and our unique protein splicing platform and its potential to unlock gene therapies for diseases that remain untreatable today,' Vila-Perelló said in a statement. The company raised €50 million in a Series A round in 2022. Gene and cell therapy startups backed by the roughly two dozen investment firms BioPharma Dive tracks have secured a little over $1.1 billion in venture dollars so far in 2025. Half of those fundings have come in the form of 'megarounds' exceeding $100 million apiece, continuing an ongoing trend. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 days ago
- Yahoo
Otsuka tops Vera with kidney drug data; Regenxbio sinks on Duchenne update
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Today, a brief rundown of news involving Otsuka Pharmaceutical and Arvinas, as well as updates from Regenxbio, Vigil Neuroscience and Sagimet Biosciences that you may have missed. Vera Therapeutics lost nearly a third of its market value Friday after Otsuka Pharmaceutical presented late-stage study data on a rival drug it's developing for the kidney disease IgA nephropathy. At a medical meeting, Otsuka said its therapy, sibeprenlimab, led to a 51% reduction in proteinuria, a key marker of kidney health, after nine months of treatment. Though cross-trial comparisons can be misleading, Vera's therapy led to a 42% reduction in proteinuria compared to placebo at a similar timepoint in its own Phase 3 study, causing investors to sell off company shares. Still, some analysts defended Vera. Jefferies' Farzin Haque cautioned not to 'overinterpret the data' and argued the two datasets 'are not clinically or statistically different for commercial uptake.' The Food and Drug Administration could approve Otsuka's drug by Nov. 28. On Monday, Vera said it intends to file an accelerated approval application in the fourth quarter. — Ben Fidler Arvinas and partner Pfizer have filed for a U.S. approval of their experimental protein-degrading drug for breast cancer, Arvinas said Friday. The two submitted the therapy, vepdegestrant, for use in people with estrogen-receptor positive, HER2 negative breast cancer and a mutation in the ESR1 gene. The application is based on Phase 3 data presented at the American Society of Clinical Oncology meeting this week showing the drug held tumors in check longer than a standard treatment. That benefit was modest, however, and wasn't observed in the overall study population. — Delilah Alvarado Regenxbio released new data Thursday showing a potential impact on muscle function among Duchenne muscular dystrophy patients who received its experimental gene therapy in an early-stage clinical trial. Regenxbio said those given the dose it's using in pivotal testing outperformed how historical data suggests they might on multiple widely used assessments of functional benefits. Still, shares fell by double digits, as some key information was missing from the update, the treatment's effects appear to be 'plateauing' and there is concern the data may not be strong enough to support an accelerated approval, wrote Jefferies analyst Maury Raycroft. Regenxbio expects to report pivotal data next year and has said it intends to seek a speedy approval afterwards, based on the therapy's ability to produce a tiny version of a muscle-protecting protein. — Ben Fidler Vigil Neuroscience reported Wednesday the failure of a mid-stage trial meant to prove its most advanced drug works as intended. The study enrolled 20 people with 'ALSP,' a rare disorder hallmarked by the erosion of white matter in the brain. All participants received Vigil's drug, VGL101, which is designed to boost the TREM2 proteins that help control inflammation in the brain. The company said that while showing favorable safety and tolerability, its treatment had no beneficial effects on important markers of effectiveness or biological activity. As such, a separate, so-called long-term extension study is being discontinued. Sanofi is in the process of acquiring Vigil for access to a different TREM2-targeting medicine. Per terms of that deal, rights to VGL101 will be returned to its original licensor, Amgen. — Jacob Bell Shares of Sagimet Biosciences have climbed nearly 40% since partner Ascletis Bioscience on Wednesday reported the company's drug denifanstat succeeded in a Phase 3 trial in China in people with moderate-to-severe acne. The drug produced 'compelling efficacy' in the trial with only mild-to-moderate side effects, which could have positive implications for its ability to treat metabolic dysfunction-associated steatohepatitis, Leerink Partners analyst Thomas Smith wrote in a research note. A 2019 partnership handed Ascletis rights in greater China to denifanstat. Sagimet could receive up to $122 million in future payments, as well as sales royalties, if the drug is approved. — Ben Fidler
Yahoo
5 days ago
- Yahoo
U of M student wins prestigious scholarship in STEM
MEMPHIS, Tenn. — College can be challenging for anyone. However, one University of Memphis sophomore is showing others that with time management and a little will power, anything is possible when achieving your goals. Blake Robinson is just like any other 20-year-old college student. When he's not studying, he's weightlifting and spending time with his friends. He's also busy conducting research at the University of Memphis, focusing on wound treatment and assisting with research at St. Jude Children's Research Hospital to find treatments for epilepsy. 'I try and look at the end goal and try to enjoy myself along the way,' said Blake Robinson. So, maybe he's not the average 20-year-old. Blake is on a mission to change lives. He's already making his mark in the world of STEM and is one of more than 400 students nationwide to receive a 2025 Goldwater Scholarship. According to the Scholarship website, the program is one of the 'oldest' and 'most prestigious' national scholarships in the STEM field in the US. Retired Memphis man gives back with free food truck meals The foundation says they look for students who have the potential to make a 'significant future contribution to research.' Blake met all of the criteria, making him the first Goldwater Scholar at the University of Memphis in over a decade. 'I think it was that continual reaching for improvement that over time really built me,' he said. The Bartlett High School graduate says that when he enrolled at the U of M, he immediately started looking at various research labs, and that's when he came across Biomedical Engineering Professor Dr. Joel Bumgardner's work. 'This is where we take shrimp exoskeleton and we're trying to turn that into a wound treatment,' Blake said. 'You could use this for surgical treatments, for burns, for military applications out in the field… sort of taking what nature already has to offer and reinventing that for medicine, that was really inspirational for me.' Blake says his interest in medicine started with his mother, who works in the medical field. 'But it really wasn't until my mother was diagnosed with two brain aneurysms, unruptured aneurysms, that I kind of looked towards research,' he said. 📡 for Memphis and the Mid-South. 📧 and have the latest top stories sent right to your inbox. Ever since, he's been working to obtain an MD-PhD in Neurosciences by participating in various research programs and shadowing different physicians. Trying to balance school, his research, and a personal life has been challenging, but he says the support of his mentors keeps him pushing forward. 'It's more so an impact of how these individuals are really pushing the field forward, as well. They're more so leading me,' said Blake. Blake has a busy year ahead of him as he plans to graduate a year early. The University says this Summer, he's heading to Cambridge, Massachusetts, to attend Harvard's Biomedical Summer Research Program. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
